secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001104659-22-126973
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Sciences FY2022 revenue up 101% to $18.2M; operating loss widens to $14.0M
--------------------------------------------------------------------------------

- Total revenue $18.2M, +101% YoY; COVID-19 testing revenue $15.5M (85% of total).
- Q4 revenue $3.6M (+17% Q/Q, +20% YoY); gross profit margin fell to 12% from 33%.
- Operating loss $14.0M vs $13.3M; adjusted EBITDA -$9.9M.
- Cash and equivalents $15.2M; secured $12M public offering and $3.7M warrant exercise in Q4.
- Company plans cGMP capacity for linearDNA platform by end of CY2023; focuses on PGx testing and UFLP Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/tm2232660d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer